A combination of remdesivir and a concentrated solution of antibodies did not work well in people hospitalized with COVID-19, according to a newly published study. The clinical trial tested remdesivir, an antiviral from Gilead Sciences, combined with anti-coronavirus hyperimmune intravenous immunoglobulin (hIVIG), the concentrated solution that, but the combination did not significantly improve favorable outcomes among the patients, researchers reported in The Lancet. The antibody solution was made using antibodies from blood plasma donated by people who recovered from COVID-19, the CCP (Chinese Communist Party) virus. About 600 patients spread across Africa, Asia, Europe, North America, and South America were divided into two cohorts for the study. About half received the experimental drug combination while the other half received a placebo and remdesivir. When measuring the outcomes among the patients after seven days following the treatment, there was little difference between the groups. Researchers reported that “there was no evidence that patients who received …